(z)-2-(2',4'-dichlorophenoxy)methyl-3-fluoroallylamine | 100496-46-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (z)-2-(2',4'-dichlorophenoxy)methyl-3-fluoroallylamine
• 英文别名: 2-(2'4'-dichlorophenoxy)methyl-3-fluoroallylamine；2-(2,4-Dichlorophenoxy)methyl-3-fluoroallylamine；(Z)-2-[(2,4-dichlorophenoxy)methyl]-3-fluoroprop-2-en-1-amine
• CAS: 100496-46-6
• 化学式: C₁₀H₁₀Cl₂FNO
• 分子量: 250.1
• InChiKey: WLDAHEFQMCTCDW-DAXSKMNVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (Z)-1-Fluoro-2-(2',4'-dichlorophenoxy)methyl-3-phthalimidopropene 在 肼 作用下， 生成 (z)-2-(2',4'-dichlorophenoxy)methyl-3-fluoroallylamine
  参考文献：
  名称：

  A general preparation of fluoroallylamine enzyme inhibitors incorporating a β-substituted heteroatom

  摘要：

  DOI：

  10.1016/s0040-4039(00)89256-4

文献信息

• Fluoroallylamine derivatives
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US04699928A1

  公开（公告）日：1987-10-13

  Fluoroallylamine derivatives of the following Formula I are novel MAO-inhibitors and at low dose levels selectively inhibit MAO-B: ##STR1## wherein: R.sub.1 and R.sub.2 independently represent hydrogen, chlorine or fluroine; R.sub.3 represents hydrogen or (C.sub.1 -C.sub.4)alkyl; and X represents oxygen or sulfur. They are useful for the treatment of depression and, co-administered with L-dopa, in the treatment of Parkinsonism.

  以下的化学式I中的氟烯丙胺衍生物是新型的MAO抑制剂，在低剂量水平上选择性地抑制MAO-B:其中：R.sub.1和R.sub.2独立地代表氢、氯或氟；R.sub.3代表氢或(C.sub.1 -C.sub.4)烷基；X代表氧或硫。它们用于治疗抑郁症，并且与L-多巴一起联合使用，可用于治疗帕金森病。
• SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF
  申请人：Pharmaxis Ltd.

  公开号：US20150158813A1

  公开（公告）日：2015-06-11

  The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.

  本文描述了替代的3-卤代烯丙胺衍生物的制备和制药用途，作为具有公式I结构的SSAO/VAP-1抑制剂。还描述了使用公式I化合物或其药学上可接受的盐或衍生物治疗各种疾病的方法，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病诱导的疾病和癌症。
• Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160244406A1

  公开（公告）日：2016-08-25

  The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

  本发明涉及制备和药物应用具有式I结构的取代3-卤代烯丙胺衍生物作为SSAO/VAP-1抑制剂。该式在说明书中定义。本发明还涉及使用式I化合物或其药学上可接受的盐或衍生物的方法，用于治疗各种疾病，例如炎症性疾病、眼部疾病、纤维化疾病、糖尿病引起的疾病和癌症。
• SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2844637B1

  公开（公告）日：2018-03-28
• US4699928A
  申请人：——

  公开号：US4699928A

  公开（公告）日：1987-10-13